Blinded Aliskiren


Combined with:

Aliskiren
Blinded NO Treatment Received
Enalapril Maleate

Indications and Reactions:

Role Indications Reactions
Primary
Cardiac Failure 59.4%
Cardiac Failure Chronic 8.0%
Cardiac Failure Congestive 3.7%
Coronary Artery Disease 3.3%
Cardiovascular Disorder 2.4%
Myocardial Infarction 2.2%
Glaucoma 2.1%
Hypertension 1.9%
Myocardial Ischaemia 1.9%
Renal Failure Chronic 1.9%
Diabetes Mellitus 1.7%
Atrial Fibrillation 1.6%
Constipation 1.5%
Prophylaxis 1.4%
Cerebral Artery Embolism 1.3%
Hyperuricaemia 1.3%
Hyperlipidaemia 1.2%
Insomnia 1.0%
Gastritis Prophylaxis 1.0%
Hypothyroidism 0.9%
Concomitant Disease Progression 17.3%
Cardiac Failure 12.7%
Hypotension 7.3%
Abdominal Pain 6.4%
Cardiac Failure Acute 5.5%
Dyspnoea 5.5%
Disease Progression 4.5%
Hyperglycaemia 3.6%
Oedema Peripheral 3.6%
Renal Failure 3.6%
Urinary Tract Infection 3.6%
Ventricular Tachycardia 3.6%
Vomiting 3.6%
Acute Pulmonary Oedema 2.7%
Asthenia 2.7%
Asthma 2.7%
Cardio-respiratory Arrest 2.7%
Chest Discomfort 2.7%
Death 2.7%
Dehydration 2.7%
Secondary
Cardiac Failure 41.1%
Cardiovascular Disorder 16.2%
Hypertension 7.0%
Cardiac Failure Chronic 6.6%
Angina Pectoris 3.4%
Cardiac Failure Acute 3.3%
Atrial Fibrillation 3.1%
Diabetes Mellitus 2.5%
Cardiac Failure Congestive 2.0%
Myocardial Ischaemia 2.0%
Type 2 Diabetes Mellitus 2.0%
Prophylaxis 1.7%
Coronary Artery Disease 1.5%
Dyslipidaemia 1.5%
Glaucoma 1.5%
Myocardial Infarction 1.3%
Heart Transplant 0.9%
Hyperlipidaemia 0.9%
Cerebral Artery Embolism 0.8%
Constipation 0.7%
Concomitant Disease Progression 18.5%
Hypotension 15.9%
Disease Progression 7.9%
Cardiac Failure 7.3%
Coronary Artery Disease 4.0%
Dizziness 4.0%
Renal Failure Acute 4.0%
Cardiac Pacemaker Insertion 3.3%
Circulatory Collapse 3.3%
Gastrointestinal Haemorrhage 3.3%
Renal Failure Chronic 3.3%
Renal Impairment 3.3%
Vertigo 3.3%
Blood Potassium Increased 2.6%
Dehydration 2.6%
Dyspnoea 2.6%
Hepatic Neoplasm Malignant 2.6%
Nephrolithiasis 2.6%
Pneumonia 2.6%
Urinary Tract Infection 2.6%

Drug Data